More recently, the SGLT2i has demonstrated an un-expected significant and consistent
effect in patients with HFrEF. The serendipity of these drugs started with the evidence of the …

An old story describes a farmer who led a contented life until he found out about the
existence of precious stones. He became so fascinated with diamonds, that he traveled …

Sodium–glucose co-transporter 2 (SGLT2) inhibitors (ie empagliflozin, canagliflozin and
dapagliflozin) are a novel class of anti-hyperglycaemic agents that have entered the …

Our understanding of the beneficial effects of sodium–glucose cotransporter 2 (SGLT2)
inhibitors in patients with heart failure (HF) is based on their clinical outcomes improvement …

In 2015, publication of the results of the BI 10773 (empagliflozin) Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) heralded the …

Heart Failure Evidence The HF benefit of SGLT2 inhibitors in people with T2D were first
observed in 3 large randomized, placebo-controlled trials evaluating canagliflozin (CANVAS …

This Focus Issue on heart failure (HF) provides novel clinically relevant information on
sodium–glucose co-transporter-2 (SGLT2) inhibitors which, initially proposed for the …

SGLT2i (Sodium-glucose co-transporter 2 inhibitors), initially developed for their glucose-
lowering potential by blocking renal tubular glucose reabsorption, have been shown to …

Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …

Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal
convoluted tubule of the nephron. These receptors are responsible for almost 90% to 95% of …